Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity

Therapeutic Drug Monitoring

Volumn 18, Issue 3, 1996, Pages 288-293

  Lee, Toong C ^a   Charles, Bruce G ^a   Steer, Peter A ^b   Flenady, Vicki J ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Mater Mother's Hospital   (Australia)

Author keywords

Caffeine; Monitoring; Neonate; Saliva; Serum

Indexed keywords

CAFFEINE CITRATE; THEOPHYLLINE DERIVATIVE;

APNEA; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; DRUG SALIVA LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEWBORN; PREMATURITY; PRIORITY JOURNAL;

APNEA; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INJECTIONS, INTRAVENOUS; MALE; PREDICTIVE VALUE OF TESTS; SALIVA;

EID: 0029955288     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199606000-00012     Document Type: Article

References (21)

1. Aranda JV, Gorman W, Bergsteinsson H, Gunn T. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr 1977;90:467-72.
2. Aranda JV, Turmen T. Methylxanthines in apnea of prematurity. Clin Perinatol 1979;6:87-108.
3. Gorodischer R, Karplus M. Pharmacokinetic aspects of caffeine in premature infants with apnoea. Eur J Clin Pharmacol 1982;22:47-52.
4. Roberts RJ. Drug therapy in infants: pharmacologic principles and clinical experience. Philadelphia: WB Saunders, 1984:119-37.
5. Cook CE, Tallent CR, Amerson EW, et al. Caffeine in plasma and saliva by a radioimmunoassay procedure. J Pharmacol Exp Ther 1976;199:679-86.
6. Haeckel R. Relationship between intraindividual variation of the saliva/plasma and of the arteriovenous concentration ratio as demonstrated by the administration of caffeine. J Clin Chem Clin Biochem 1990;28:279-84.
7. Khanna NN, Somani SM, Boyer A, Miller J, Chua C, Menke JA. Cross validation of serum to saliva relationships of caffeine, theophylline and total methylxanthines in neonates. Devel Pharmacol Ther 1982;4:18-27.
8. Somani SM, Khanna NN. Methylxanthines in serum, saliva, and spinal fluid of premature infants. Semin Perinatol 1981;5:346-50.
9. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9:503-12.
10. Murphy MG, Peck CC, Conner DP, Zamani K, Merenstein GB, Rodden D. Transcutaneous theophylline collection in preterm infants. Clin Pharmacol Ther 1990;47:427-34.
11. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva. Clin Pharmacokinet 1992;23:365-79.
12. Wood JH, Flora KP, Narasimhachavi A, Baker CA. Dependence of salivary drug concentration on salivary flow rate. Meth Find Exp Clin Pharmacol 1982;4:255-60.
13. Mucklow JC, Bending MR, Kahn BC, Dollery CT. Drug concentration in saliva. Clin Pharmacol Ther 1978; 24:563-70.
14. Zuidema J, van Ginneken CAM. Clearance concepts in salivary drug excretion. Pharm Acta Helv 1983;58:88-143.
15. Chiou WL, Chang K, Peng GW. Precaution in the monitoring of drug levels in saliva: abnormal salicylate levels after oral dosing. J Clin Pharmacol 1976;16:158-60.
16. Fredholm BB. Gastrointestinal and metabolic effects of methylxanthines. Prog Clin Biol Res 1984;158:331-54.
17. Ryu JE. Caffeine in human milk and in serum of breast-fed infants. Devel Pharmacol Ther 1985;8:329-37.
18. Pfeifer RW, Notari RE. Predicting caffeine plasma concentrations resulting from consumption of food or beverages: a simple method and its origin. Drug Intell Clin Pharm 1988;22:953-9.
19. Tyrala EE, Dodson WE. Caffeine secretion into breast milk. Arch Dis Child 1979;54:787-800.
20. Scanlon JEM, Chin KC, Morgan MEI, Durbin GM, Hale KA, Brown SS. Caffeine or theophylline for neonatal apnoea? Arch Dis Child 1992;67:425-8.
21. Aranda JV, Cook CE, Gorman W, et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnoea. J Pediatr 1979;94:663-8.